Trial Profile
A Phase II Study of the Combination of Ofatumumab and Ibrutinib Followed by Allogeneic Bone Marrow Transplant or Consolidation for Pretreated High Risk Patients With Chronic Lymphocytic Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 06 Sep 2021 Planned End Date changed from 1 Nov 2020 to 1 Aug 2025.
- 06 Sep 2021 Planned primary completion date changed from 1 Nov 2020 to 1 Aug 2025.
- 05 Oct 2020 Status changed from recruiting to active, no longer recruiting.